Consumer Reports February issue says all 13 calcium carbonate supplements tested for lead met the California Prop 65 level of 4 mcg lead/1,000 mg calcium. However, only six met the more stringent 1.5 mcg limit that goes into effect in April. The supplements found to contain less than 1 mcg lead were: Tums Antacid/Calcium Supplement Regular Strength, Tums 500, AARP Formula 314, AARP Formula 564 with Vitamin D, Walgreens Pharmaceutical Grade and Your Life Natural Source. Those containing 2-3 mcg lead were: Rolaids Antacid, American Fare Vita Smart (Kmart), Vita-Smart Natural Oyster Shell (Kmart), CVS Natural Oyster Shell, Rite Aid USP 600 mg, Thrifty Payless Calcium 600 and Your Life Natural Oyster Shell. The Vita-Smart and Thrifty Payless products have since been reformulated, Consumer Reports notes. California settled with calcium supplement makers over the lead levels in their products in 1997 ("The Tan Sheet" April 28, 1997, p. 1)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
